Protagenic Therapeutics, Inc.\new
Protagenic Therapeutics, Inc. is a U.S.-based development-stage biopharmaceutical company focused on neuropeptide-based therapies. Its lead program, PT00114, is a synthetic form of TCAP being developed for neuropsychiatric disorders such as depression, anxiety, PTSD, and substance use-related conditions.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenuePT00114, a synthetic TCAP-based compound being developed for neuropsychiatric indications.
Additional TCAP-family compounds under research and development.
Discovery, animal studies, and IND-enabling work for neuropeptide programs.
Customers
Protagenic does not sell commercial products in the traditional sense; its primary counterparties are clinical trial participants, research vendors, and regulatory agencies supporting drug development. If successful, its eventual customers would be physicians, hospitals, and patients in neuropsychiatric treatment markets.
Healthy volunteers and patients enrolled in Phase I/IIa studies to evaluate safety, biomarkers, and early efficacy.
Contract research organizations, peptide synthesizers, and other outsourced service providers used to advance the pipeline.
FDA and other regulators that review preclinical, IND, and clinical data before commercialization can proceed.
Potential end users of PT00114 if the program reaches approval for depression, anxiety, PTSD, or addiction-related conditions.
Strategy
Protagenic's strategy is to advance PT00114 through clinical development and obtain regulatory approval for commercialization. It is also building a broader TCAP-family pipeline and protecting the intellectual property around its neuropeptide platform.
Clinical data are the main value driver for a development-stage biotech company.
Regulatory clearance is required before broader testing and eventual commercialization.
A second or third asset can reduce single-program dependence and extend platform value.
Geography
Protagenic is headquartered in the United States and conducts its development activities through a U.S.-centric clinical and regulatory framework. The company also references regulatory questions in Germany, indicating some cross-border scientific or regulatory interaction, but no country-level revenue disclosure is available.
Risks
Protagenic faces the typical risks of an early-stage biotech company: clinical failure, regulatory delay, and dependence on external funding. Its lead asset is still in development, so setbacks in safety, efficacy, or trial execution could materially impair the business.
- Going concern and financing dependenceImpact: CriticalLikelihood: High
The company has limited cash and expects to need additional capital to fund operations.
Exposure: Corporate funding and continuity of development programs
- Clinical development failureImpact: HighLikelihood: High
PT00114 must demonstrate acceptable safety and efficacy in human trials.
Exposure: Lead asset value and pipeline viability
- Regulatory delay or rejectionImpact: HighLikelihood: High
Approval pathways depend on FDA and other regulator feedback and compliance.
Exposure: Trial timelines and commercialization prospects
- Single-program concentrationImpact: HighLikelihood: High
The company's value is concentrated in one lead candidate and a small pipeline.
Exposure: Business model resilience
- Outsourced development execution riskImpact: MediumLikelihood: Medium
CROs, synthesizers, and other vendors are essential to preclinical and clinical work.
Exposure
Accounting
Judgemental itemsMost spending is tied to external CROs, peptide synthesis, and development work, so timing of invoices and milestones affects quarterly results.
Impact: Operating loss and cash burn
Option vesting creates non-cash expense that can materially affect reported losses in a small company.
Impact: Operating expenses and net loss
Legal, accounting, and consultant costs are significant for a public biotech and may be recognized before cash payment.
Impact: Working capital and liabilities
Management must assess whether available cash is sufficient to fund operations for the next twelve months.
Impact: Financial statement presentation and investor risk assessment
Similar listed companies
Publicly listed companies with a comparable business focus.
Oragenics Inc
OGEN · Pharmaceutical Preparations
Enveric Biosciences, Inc.
ENVB · Pharmaceutical Preparations
Tectonic Therapeutic, Inc.
TECX · Biological Products, (No Diagnostic Substances)
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Last updated: 24/09/2026